{"entity":{"id":"pixantrone","kind":"drug","name":"Pixantrone","aka":["BBR 2778","Pixantrone dimaleate"],"tldr":"Pixantrone is an anthracycline-like drug engineered to spare the heart. The European Union authorised it in 2012 as a single agent for adults with aggressive B-cell lymphoma that had relapsed several times; the authorisation expired in June 2024 when the company did not renew it.","summary":"Pixantrone was granted conditional marketing authorisation in the European Union in 2012 for adults with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma, based on the PIX301 trial in which it produced more complete responses than other single agents. Because it lacks the anthracycline quinone, it causes less cardiotoxicity than doxorubicin in animal models, which allows treatment of patients who have already had a full lifetime dose of anthracyclines. The FDA did not approve it. The EU authorisation stayed conditional and expired on 12 June 2024 after Les Laboratoires Servier chose not to apply for renewal, citing lack of demand, so pixantrone is no longer authorised anywhere.","status":"withdrawn","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Pixantrone","links":[{"label":"EMA product page","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Pixantrone"},{"label":"ChEMBL CHEMBL1201855","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201855"}],"tags":["gap-fill","chembl-universe"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":["top2a"],"drugs":["doxorubicin"],"companies":["servier"],"institutions":[],"pathways":[],"terms":[],"trials":["nct01086605","nct03458260"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Pixuvri","modality":"Aza-anthracenedione cytotoxic, intravenous","mechanism":"A DNA intercalator and topoisomerase II poison designed to keep the antitumour activity of the anthracyclines while removing the iron-binding quinone that drives their cardiotoxicity.","approvals":[{"region":"EU","year":2012,"indication":"Multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma, single agent (conditional)","note":"Authorisation expired 12 June 2024; the holder did not apply for renewal"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pixantrone/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"target":[{"id":"top2a","kind":"target","name":"Topoisomerase II alpha (TOP2A)","route":"/targets/top2a/"}],"drug":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"}],"company":[{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/"}],"trial":[{"id":"nct01086605","kind":"trial","name":"Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer","route":"/trials/nct01086605/"},{"id":"nct03458260","kind":"trial","name":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","route":"/trials/nct03458260/"}]}}